Clinical activity of <scp>CC‐90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies

Abstract

The safety profile of CC-90011 suggested that its reversible mechanism of action may provide an advantage over other irreversible LSD1 inhibitors. The favorable tolerability profile, clinical activity, durable responses, and once-per-week dosing support further exploration of CC-90011 as monotherapy and in combination with other treatments for patients with advanced solid tumors and other malignancies.